Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

SIM1803-1A

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Simcere, WuXi AppTec

Drug class:

ROS1 inhibitor, Trk inhibitor

Related drugs:

NTRK3 fusion	Solid Tumor	NTRK3 fusion	Solid Tumor	SIM1803-1A Sensitive: D – Preclinical SIM1803-1A Sensitive : D	SIM1803-1A Sensitive: D – Preclinical SIM1803-1A Sensitive : D
NTRK2 fusion	Solid Tumor	NTRK2 fusion	Solid Tumor	SIM1803-1A Sensitive: D – Preclinical SIM1803-1A Sensitive : D	SIM1803-1A Sensitive: D – Preclinical SIM1803-1A Sensitive : D
NTRK1 fusion	Solid Tumor	NTRK1 fusion	Solid Tumor	SIM1803-1A Sensitive: D – Preclinical SIM1803-1A Sensitive : D	SIM1803-1A Sensitive: D – Preclinical SIM1803-1A Sensitive : D
ROS1 fusion	Solid Tumor	ROS1 fusion	Solid Tumor	SIM1803-1A Sensitive: D – Preclinical SIM1803-1A Sensitive : D	SIM1803-1A Sensitive: D – Preclinical SIM1803-1A Sensitive : D
SDC4-ROS1 fusion	Non Small Cell Lung Cancer	SDC4-ROS1 fusion	Non Small Cell Lung Cancer	SIM1803-1A Sensitive: D – Preclinical SIM1803-1A Sensitive : D	SIM1803-1A Sensitive: D – Preclinical SIM1803-1A Sensitive : D